Total results651
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD1A | P06126 | T-cell surface glycoprotein CD1a (T-cell surface antigen T6/Leu-6) (hTa1 thymocyte antigen) (CD antigen CD1a) | CD markersPredicted membrane proteins | 1 | Aplastic anaemiaAtopic eczema | Clinical-translation mediationFusion and delivery mediationImmune mediation | 0 | 0.47 | ||
| CFTR | P13569 | Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 5.6.1.6) (cAMP-dependent chloride channel) | Cancer-related genesDisease related genesEnzymes | 12 | Bowel habit changeChronic obstructive pulmonary diseaseCystic fibrosis | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 0 | 0.47 | ||
| CLD1 | O95832 | Claudin-1 (Senescence-associated epithelial membrane protein) | Disease related genesHuman disease related genesPotential drug targets | 4 | Ichthyosis | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 0 | 0.47 | ||
| CLD6 | P56747 | Claudin-6 (Skullin) | 4 | Solid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 0 | 0.47 | |||
| CNGA1 | P29973 | Cyclic nucleotide-gated channel alpha-1 (CNG channel alpha-1) (CNG-1) (CNG1) (Cyclic nucleotide-gated channel, photoreceptor) (Rod photoreceptor cGMP-gated cation channel subunit alpha) (cGMP-gated cation channel alpha-1) | 7 | Myelopathy | Clinical-translation mediationFusion and delivery mediation | 0 | 0.47 | |||
| CRUM2 | Q5IJ48 | Protein crumbs homolog 2 (Crumbs-like protein 2) | Disease related genesHuman disease related genesPotential drug targets | 1 | Retinitis pigmentosa | Adhesion and uptake mediationFusion and delivery mediation | 0 | 0.47 | ||
| CTNA2 | P26232 | Catenin alpha-2 (Alpha N-catenin) (Alpha-catenin-related protein) | Disease related genesHuman disease related genesPlasma proteins | Lissencephaly | Fusion and delivery mediation | 0 | 0.47 | |||
| CXB1 | P08034 | Gap junction beta-1 protein (Connexin-32) (Cx32) (GAP junction 28 kDa liver protein) | Disease related genesHuman disease related genesPotential drug targets | 4 | Charcot-Marie-Tooth diseaseDejerine-Sottas syndrome | Fusion and delivery mediation | 0 | 0.47 | ||
| CXCR4 | P61073 | C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (FB22) (Fusin) (HM89) (LCR1) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (Lipopolysaccharide-associated protein 3) (LAP-3) (LPS-associated protein 3) (NPYRL) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (CD antigen CD184) | 7 | Acute myeloid leukaemiaBreast cancerChronic arterial occlusive disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 0 | 0.47 | |||
| DMD | P11532 | Dystrophin | Cancer-related genesDisease related genesFDA approved drug targets | CardiomyopathyCystic fibrosisEpilepsy/seizure | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 0 | 0.47 |